Our study found that CAP (1 mg/kg, intraperitoneal injection for 1 week), as an activator of TRPV1, could decrease the apoptosis of neuron, inhibit the expression of BAX, Caspase3, and Cleaved-Caspase3 and increase the expression of anti-apoptotic protein Bcl-2 in the hippocampus and prefrontal cortex of MS rats, which might demonstrate the anti-apoptotic effect of CAP in our model of MS. Here, BCL2 is linked to myeloid sarcoma.